Bone protein can inhibit prostate cancer

18 November 2015

Researchers from the Lawrence Livermore National Laboratory have discovered that Sclerostin (SOST), a protein commonly found in bones, can help to prevent prostate cancer from metastasising.

When prostate cancer spreads, it often forms new tumours in the skeleton. These can be extremely painful, and they also cause 70 per cent of all deaths from the disease.

The scientists found that bones that have low levels of SOST are particularly vulnerable to cell migration and invasion, which are the mechanisms by which cancers are able to spread.

A follow-up study revealed that SOST was also able to prevent the spread of prostate cancer in vitro. This surprised the researchers, as it had previously been suggested that bones offered a rich environment for cancer cells to replicate. However, it appears that only bones with low levels of SOST are particularly vulnerable.

It is hoped that this discovery could lead to the development of new prostate cancer treatments in the future.

Posted by Edward Bartel


Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)